子宫内暴露于秋水仙碱后的妊娠结局。

Pregnancy outcome after in utero exposure to colchicine.

机构信息

Israeli Teratology Information Service and Israel Ministry of Health, Jerusalem, Israel.

出版信息

Am J Obstet Gynecol. 2010 Aug;203(2):144.e1-6. doi: 10.1016/j.ajog.2010.02.063. Epub 2010 Jul 1.

DOI:10.1016/j.ajog.2010.02.063

PMID:20579964

Abstract

OBJECTIVE

We sought to examine the fetal safety of colchicine.

STUDY DESIGN

This was a prospective observational comparative cohort study regarding colchicine exposure during pregnancy including contacts to 2 Teratology Information Services in Israel from 1994 through 2006.

RESULTS

In all, 238 colchicine-exposed pregnancies (97.0% first trimester) and 964 pregnancies with nonteratogenic exposure were followed up. Treatment indications were: familial Mediterranean fever (87.3%), Behçet disease (7.5%), or other (5.2%). The rate of major congenital anomalies was comparable between the groups (10/221 [4.5%] vs 35/908 [3.9%]; P = .648). There were no cytogenetic anomalies in the colchicine group. The median gestational age at delivery was earlier (39 [38-40] vs 40 [38-41] weeks; P < .001), the rate of preterm deliveries was higher (32/214 [15.0%] vs 51/867 [5.9%]; P < .001), and the median birthweight was lower (3000 [2688-3300] vs 3300 [2900-3600] g; P < .001) in the colchicine group.

CONCLUSION

The present study suggests that colchicine does not appear to be a major human teratogen, and, probably, has no cytogenetic effect.

摘要

目的

我们旨在研究秋水仙碱的胎儿安全性。

研究设计

这是一项前瞻性观察性比较队列研究，涉及 1994 年至 2006 年期间以色列 2 个致畸信息服务机构的秋水仙碱暴露妊娠，共随访 238 例秋水仙碱暴露妊娠（97.0%为孕早期）和 964 例非致畸暴露妊娠。治疗指征为：家族性地中海热（87.3%）、贝切特病（7.5%）或其他疾病（5.2%）。两组主要先天性畸形的发生率无差异（10/221 [4.5%] 与 35/908 [3.9%]；P =.648）。秋水仙碱组无细胞遗传学异常。分娩时的中位孕龄较早（39 [38-40] 与 40 [38-41] 周；P <.001），早产率较高（32/214 [15.0%] 与 51/867 [5.9%]；P <.001），出生体重较低（3000 [2688-3300] 与 3300 [2900-3600] g；P <.001）。